These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Hany M; Oehen S; Schulz M; Hengartner H; Mackett M; Bishop DH; Overton H; Zinkernagel RM Eur J Immunol; 1989 Mar; 19(3):417-24. PubMed ID: 2468501 [TBL] [Abstract][Full Text] [Related]
4. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. Klavinskis LS; Whitton JL; Oldstone MB J Virol; 1989 Oct; 63(10):4311-6. PubMed ID: 2476571 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608 [TBL] [Abstract][Full Text] [Related]
6. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Clegg JC; Lloyd G Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642 [TBL] [Abstract][Full Text] [Related]
7. Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. La Posta VJ; Auperin DD; Kamin-Lewis R; Cole GA J Virol; 1993 Jun; 67(6):3497-506. PubMed ID: 7684468 [TBL] [Abstract][Full Text] [Related]
8. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice. Hashizume M; Takashima A; Iwasaki M J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352 [TBL] [Abstract][Full Text] [Related]
9. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340 [TBL] [Abstract][Full Text] [Related]
10. Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. Castrucci MR; Hou S; Doherty PC; Kawaoka Y J Virol; 1994 Jun; 68(6):3486-90. PubMed ID: 7514676 [TBL] [Abstract][Full Text] [Related]
11. Induction of specific CD8+ memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope. Shams H; Poblete F; Rüssmann H; Galán JE; Donis RO Vaccine; 2001 Nov; 20(3-4):577-85. PubMed ID: 11672924 [TBL] [Abstract][Full Text] [Related]
12. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. Oehen S; Waldner H; Kündig TM; Hengartner H; Zinkernagel RM J Exp Med; 1992 Nov; 176(5):1273-81. PubMed ID: 1402673 [TBL] [Abstract][Full Text] [Related]
13. Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Goossens PL; Milon G; Cossart P; Saron MF Int Immunol; 1995 May; 7(5):797-805. PubMed ID: 7547706 [TBL] [Abstract][Full Text] [Related]
14. Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization. Hassett DE; Slifka MK; Zhang J; Whitton JL J Virol; 2000 Sep; 74(18):8286-91. PubMed ID: 10954526 [TBL] [Abstract][Full Text] [Related]
15. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. Yokoyama M; Zhang J; Whitton JL J Virol; 1995 Apr; 69(4):2684-8. PubMed ID: 7884923 [TBL] [Abstract][Full Text] [Related]
16. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729 [TBL] [Abstract][Full Text] [Related]
17. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. Seiler P; Bründler MA; Zimmermann C; Weibel D; Bruns M; Hengartner H; Zinkernagel RM J Exp Med; 1998 Feb; 187(4):649-54. PubMed ID: 9463415 [TBL] [Abstract][Full Text] [Related]
18. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines. Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555 [TBL] [Abstract][Full Text] [Related]
19. Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge. Hassett DE; Zhang J; Whitton JL J Virol; 1997 Oct; 71(10):7881-8. PubMed ID: 9311877 [TBL] [Abstract][Full Text] [Related]